Almonty, 2G Energy and Redcare Pharmacy: Three Exciting Stocks with Fresh Momentum
Allied Raw Materials and the Battle for a Turnaround: adesso, INDUS, Strategic Resources
Drill Deep, Plug Wells, Manage Risk: How Daldrup, Zefiro and Munich Re Make Money from Climate Protection
Infineon Slides, Chinese Anchor Investor at Puma, and a Potential Chart Breakout at HPQ Silicon! Where Are the Opportunities for Your Portfolio?
After 600% Gains with Moderna! Cardiol Therapeutics Poised for a Revaluation - Analysts See Significant Upside Potential
Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!
Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom
Commented by Lars Winter on October 12th, 2026 | 05:45 CEST
Almonty, 2G Energy and Redcare Pharmacy: Three Exciting Stocks with Fresh Momentum
New orders, higher forecasts, and the transition from project developer to producer: The news outlook for Almonty Industries, 2G Energy, and Redcare Pharmacy has improved significantly recently. The three companies serve completely different markets. What they have in common is that they must now translate high expectations into measurable growth. We take a closer look at these three stocks.
Read
Commented by Stefan Bode on October 12th, 2026 | 05:42 CEST
Allied Raw Materials and the Battle for a Turnaround: adesso, INDUS, Strategic Resources
The race for competitive technologies, strategic raw materials and the right moment on the chart is driving companies and investors alike. One stock in today's report is targeting the key resistance line again for the first time in months after a price decline; another must prove, after a spectacular rally, that its profit jump is more than a one-off commodity effect. A third, barely noticed stock is betting on vanadium for green steel and fast-charging batteries. Whether a comeback, a test or a quiet beacon of hope, opportunities and risks must be carefully weighed up.
Read
Commented by Jens Castner on October 12th, 2026 | 05:39 CEST
Drill Deep, Plug Wells, Manage Risk: How Daldrup, Zefiro and Munich Re Make Money from Climate Protection
Created and Published on Behalf of Zefiro Methane Corp.
What was long considered a quiet environmental problem is growing into a market whose size in the United States alone is estimated at up to USD 280 billion. In Germany, thousands of abandoned oil and gas wells lie in the ground, while in the US there are millions. Many pollute the atmosphere with methane, a climate-killing gas. For drilling services provider Daldrup & Söhne, plugging old wells represents a new business line, although growth is being driven primarily by the geothermal energy boom. Canadian specialist Zefiro Methane, by contrast, focuses entirely on the remediation of orphaned wells in the US and generates additional revenue from CO₂ credits. Munich Re is active in both markets.
Read
Commented by Matthias Schomber on October 12th, 2026 | 05:37 CEST
Infineon Slides, Chinese Anchor Investor at Puma, and a Potential Chart Breakout at HPQ Silicon! Where Are the Opportunities for Your Portfolio?
Nervousness is rising across the markets. Share prices are being driven by major investors taking stakes, the AI boom, political statements, and the latest developments in the war. While chip giant Infineon is benefiting from a massive AI boost despite market turbulence, China's Anta is gaining influence at Puma and could give the sporting goods manufacturer exactly the fresh momentum it needs. Meanwhile, Canadian technology company HPQ Silicon is approaching a critical technical resistance level. A breakout could open the door to significant upside potential. What opportunities do these three very different stocks offer, and where might an entry point be worthwhile?
Read
Commented by Fabian Lorenz on October 12th, 2026 | 05:30 CEST
After 600% Gains with Moderna! Cardiol Therapeutics Poised for a Revaluation - Analysts See Significant Upside Potential
With gains of more than 600%, Moderna is the Nasdaq’s best-performing stock so far this year. Much of its future growth potential may already be priced in, prompting Citigroup to recommend selling shares in the mRNA specialist. Analysts, however, see significant upside potential in another biotech company: Cardiol Therapeutics. The Canadian biotechnology company focuses on inflammatory heart diseases, and its lead drug candidate, CardiolRx™, is already in Phase 3 clinical trials. Following strong Phase 2 data, the stock more than doubled between July and September. After a subsequent pullback, could this present an attractive entry opportunity? In a recent interview, the CEO explains why he remains optimistic. Two research firms recommend buying the stock and see the potential for a multiple-fold increase in its share price.
Read
Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST
Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!
New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?
Read
Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST
Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom
When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.
Read
Commented by Stefan Feulner on October 12th, 2026 | 05:22 CEST
Osisko Metals, Globex Mining, Critical Metals – Billion-Dollar Potential Underground
Gold remains in demand as a safe-haven metal, copper is becoming indispensable for power grids and AI infrastructure, and the West wants to break free of its dependence on China for rare earths. This is increasingly putting raw material deposits at the centre of strategic investment. Yet new mines do not emerge overnight. Exploration, permits and financing determine who can actually benefit from rising demand. Particularly interesting are companies that already control large deposits or participate in new discoveries through equity stakes and royalties.
Read
Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST
BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk
The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.
Read
Commented by Fabian Lorenz on October 9th, 2026 | 10:55 CEST
Steel Is Shining Again! Can thyssenkrupp Gain Another 100%? Will Salzgitter and Strategic Resources Be Next?
A 100% share-price gain in just four months? Few investors would have expected such a performance from thyssenkrupp—but that is exactly what has happened! One reason is the renewed outlook for green steel, a trend Salzgitter is also banking on. The company is pushing ahead with the transformation of its steel production, yet its stock has not taken off—at least not yet. And who else could benefit if steel companies like thyssenkrupp switch their production to more climate-friendly processes? One intriguing candidate is Strategic Resources. The Canadian company aims to supply a key raw material for the green steel industry. With a project in Québec, Strategic Resources could position itself as a supplier to the steel industry of the future. Could its stock be ready to take off, too?
Read
Commented by Tarik Dede on October 9th, 2026 | 09:10 CEST
Drones, AI and Gold: Samsung, Volatus Aerospace and Equinox Gold in Focus
These are turbulent times for the stock markets. Interest rates are rising, bank stocks are weakening, and the number of mega-IPOs, including SpaceX and Anthropic, keeps growing. Parallels with previous stock-market crashes are becoming increasingly apparent. Yet many investors are still riding a wave of euphoria. The current bull market is already the longest in US stock-market history, driven largely by artificial intelligence. But the downside is becoming increasingly evident: valuations are high, and concentration in the major stock indices is enormous. Consider just one example: ten stocks, the so-called Magnificent Seven, along with Broadcom, AMD, and Micron, now account for 42% of the S&P 500. At these levels, there is little room for anything to go wrong. Even in this market environment, however, opportunities and risks coexist. Today, we take a closer look at Samsung, Volatus Aerospace and Equinox Gold.
Read
Commented by Carsten Mainitz on October 9th, 2026 | 09:05 CEST
Weight-Loss Drugs 2.0: Can BioNxt and Merck Catch Up with Novo Nordisk and Eli Lilly? What About BioNTech?
The boom in weight-loss drugs is creating a billion-dollar market within the pharmaceutical industry, with an annual volume of USD 100 billion. Novo Nordisk and Eli Lilly are battling for dominance, while Merck is also entering the fray, albeit still in the early stages. BioNxt Solutions aims to deliver established active ingredients via a dissolvable film, targeting enormous potential with a comparatively low-risk approach. For BioNTech, a substantial cash reserve will determine how much time the company has to deliver its next growth spurt. Where does the greatest stock-market opportunity lie?
Read
Commented by Tarik Dede on October 9th, 2026 | 09:00 CEST
Copper in the Spotlight: BHP, Southern Copper and Power Metallic Mines
Copper prices remain elevated despite ongoing market volatility. Recent developments in the physical market have provided plenty of reasons for concern. Production in Chile, by far the world's largest copper-producing country, remains subdued and is declining at some operations. Strikes are looming at several mines. Most recently, Antofagasta reported the start of a work stoppage at its Centinela mine in the Andean nation. Adding to these concerns, Deutsche Bank's commodities team highlighted the geopolitical aspects in a recent study. Copper is essential to virtually every sector of the economy, from construction and power grids to manufacturing and AI data centres. According to the study, the US and China now control, directly or indirectly, 70% of global copper production. This presents a challenge for Europe and many other regions, where securing reliable supplies of critical raw materials remains a key strategic priority. Against this backdrop, we take a closer look at the copper market and the geopolitical tensions shaping it through three stocks: Power Metallic Mines, BHP and Southern Copper.
Read
Commented by Fabian Lorenz on October 9th, 2026 | 07:30 CEST
Deutz Stock Under Pressure! Buy Recommendations for Bayer and Partner MustGrow Biologics
Created and Published on Behalf of MustGrow Biologics Corp.
What is going on with Deutz? The Cologne-based company had emerged as a favourite among investors looking to capitalize on the defence boom. But after more than doubling in just a few months, the stock has recently fallen by around 20%. There are clear reasons for the pullback—but should investors be worried? There is certainly reason for optimism at MustGrow. The US commercialization of the soil-fertility product TerraSante™ has begun, and demand is outpacing supply. Contract manufacturers now need to ramp up production quickly. Analysts expect revenues and earnings to rise sharply in the coming years. A partnership with Bayer is also expected to contribute to this growth. Bayer, meanwhile, plans to expand its US presence with a multibillion-dollar investment. The stock is not currently benefiting from this development. Nevertheless, analysts are recommending the shares as a Buy.
Read
Commented by Stefan Bode on October 9th, 2026 | 07:25 CEST
Between New Beginnings and a Test of Resilience: Almonty Industries, Aumovio and SUSS MicroTec
A surprising leadership change, strategically critical raw materials, and record orders amid falling share prices: Three publicly traded companies show how closely opportunities and risks are currently intertwined. While an automotive supplier struggles to improve margins, a tungsten producer is expanding its Western supply chains, and a semiconductor equipment manufacturer is tapping into new markets. Which developments justify optimism—and where must investors remain patient? This report examines what could be decisive for the next price movement.
Read